ElaineTLamMDFACP

Genitourinary Oncology

Associate Professor, Medicine, University of Colorado School of Medicine

Overview of Dr. Lam

Dr. Elaine Lam is a medical oncologist in Aurora, CO and is affiliated with University of Colorado Hospital. She received her medical degree from University of Colorado Denver School of Medicine and has been in practice 14 years. She specializes in genitourinary medical oncology.

Office
1665 Aurora Ct
Aurora, CO 80045
Book by Phone+1(720) 818-7438

Fax+1 720-848-0180

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2010
University of ColoradoResidency, Internal Medicine, 2003 - 2006
University of Colorado School of Medicine Anschutz Medical CampusClass of 2003

Certifications & Licensure

CO State Medical License 1998 - 2025
WY State Medical License 2021 - 2025
OH State Medical License 2007 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow of the American College of Physicians American College of Physicians, 2018

Clinical Trials

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma Start of enrollment: 2017 Aug 01
Completed
Phase 2
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Start of enrollment: 2017 Jul 07
Completed
Phase 3
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2017 Sep 28
Active, not recruiting
Phase 1, Phase 2
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread Start of enrollment: 2018 Mar 08
Active, not recruiting
Phase 1, Phase 2
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) Start of enrollment: 2019 Jan 08
Active, not recruiting
Phase 2
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Start of enrollment: 2019 Jun 07
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

8 citations
Collision renal cell papillary and medullary carcinoma in a 66-year-old man.
Elaine T. Lam, Elizabeth R. Kessler, Thomas W. Flaig, Francisco G. La Rosa
Oncology. 2013-09-16
173 citations
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg, Sylvestre Le Moulec, Stéphane Oudard
Journal of Clinical Oncology. 2016-09-27
15 citations
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw
Journal of the National Comprehensive Cancer Network. 2024-02-01

Press Mentions

‘She Cares’: A CU Department of Medicine Doctor Celebrates a Patient’s 100th BirthdayFebruary 29th, 2024

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Multiplan PPO
Rocky Mountain Group/Indiv - HMO/Private Pay
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment